Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: lindalib who wrote (3019)	7/12/2010 11:57:41 AM
From: Jibacoa	1 Recommendation Read Replies (1) \| Respond to of 3722

CYTR was helped last month by the inclusion on the Russell 3000 and the patent on Bafetinib The ACTAY remains at $2.33 And it seems it could get back above the resistance at the $0.80 level.<g> bigcharts.marketwatch.com RXII has continued to have much heavier downside volumes. The highest one was on March 23 (3,246,700) the more recent one on June 30 (2,183,600) The stock dropped below its support at the $4 level on May 21 and is now trying to find support at $2.<g> bigcharts.marketwatch.com RXII claims its delivery of sd-rxRNA to retinal cells in the mouse eye was effective.And as mentioned, it said that its therapeutic platform has the potential to be broadly applicable to multiple therapeutic areas. The ACTAY is now at $11.33 As mentioned, RXII was able to trim some its loss on the 1stQ and the ELs for 2010 & 2011 which have been increased, are around $0.95 & $0.80 vs. $1.24 in 2009 I would now lower the TT to $4 pending further developments, and that would be a 100% gain from present levels.<g> But with some good news, and a better general market,the stock could still get to the $5 level.<g> bigcharts.marketwatch.com Bernard